Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib

INTRODUCTION: Pivotal phase III trials have positioned angiogenesis inhibitors as first-line therapy for the management of most advanced or metastatic renal cell carcinomas (mRCC). Approaches to second-line therapy, however, remain more controversial with respect to drug selection and drug sequencin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Can Urol Assoc J
Main Authors: Richter, Suzanne, Seah, Jo-An, Pond, Gregory R., Gan, Hui K., Mackenzie, Mary J., Hotte, Sebastien J., Mukherjee, Som D., Murray, Nevin, Kollmannsberger, Christian, Heng, Daniel, Haider, Masoom A., Halford, Robert, Ivy, S. Percy, Moore, Malcolm J., Sridhar, Srikala. S.
Formato: Artigo
Idioma:Inglês
Publicado em: Canadian Medical Association 2014
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4277518/
https://ncbi.nlm.nih.gov/pubmed/25553152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.2426
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados